Bio Pharma R&D Stays Strong Despite Economics
05/04/2010
PhRMA-member companies alone spent an estimated $45.8 billion on pharmaceutical R&D last year, according to the survey. The Burrill & Company analysis shows that non-PhRMA pharmaceutical research companies in the United States spent an estimated $19.5 billion on R&D in 2009.
While companies have been forced to make difficult business decisions, research spending as a percentage of sales remained high in 2009. Over the past nine years, America's pharmaceutical research companies have consistently invested around 18 percent of domestic sales on R&D activities.
"America's biopharmaceutical research sector takes great pride in its global leadership in the development of new life-saving treatments and cures," said PhRMA President and CEO Billy Tauzin.
Project Announcements
United Arab Emirates-Based Hotpack Plans Edison, New Jersey, Manufacturing Operations
05/12/2025
SSAB Expands Axis, Alabama, Production Operations
05/12/2025
Carnival Corporation Plans Miami, Florida, Headquarters Operations
05/12/2025
Merck Animal Health Expands De Soto, Kansas, Manufacturing Operations
05/12/2025
Oxford Technologies Plans Bay County, Florida, Manufacturing Operations
05/12/2025
PPG Plans Shelby, North Carolina, Manufacturing Operations
05/12/2025
Most Read
-
Run a Job Task Analysis
Q4 2024
-
39th Annual Corporate & 21st Annual Consultants Surveys: What Business Leaders and Consultants Are Saying About Site Selection
Q1 2025
-
The Location Economics of Advanced Nuclear
Q1 2025
-
Why Workforce Readiness Can’t Wait
Q1 2025
-
Power, Policy, and Site Selection in 2025
Q1 2025
-
Is It Time to Start Planning for Quantum Data Centers?
Q1 2025
-
Top States for Doing Business in 2024: A Continued Legacy of Excellence
Q3 2024